Recently, the Category 1 innovative product Ganagliflozin Proline Tablets (trade name: 惠优静) of Jilin Huisheng Biopharmaceutical Co,. Ltd. was approved for marketing by China NMPA. It is indicated to improve the blood sugar control for adult patients with type 2 diabetes by singe use or combined use with metformin hydrochloride.

The Ganagliflozin Proline Tablets is a sodium glucose co-transporter 2 (SGLT2) inhibitor that inhibits SGLT2, reduces the re-absorption of filtered glucose, lowers the renal threshold of glucose, and thus increases urine glucose excretion. The marketing of this drug provides a new treatment option for adult patients with type 2 diabetes.